
With promising news and increased expectations Zealand Pharma has once again shown its success to investors. It indicates that the biotech company is entering a significant stage in its maturity, says CEO David Solomon.
“The interesting part is that we guided for profitability in 2012, and we were profitable in 2011. Two years in a row we set the bar for a maturing biotech company like Zealand. We are actually doing business in the next generation of the biotech world,” David Solomon tells Medwatch.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app